Bausch Health Companies Inc. · TSX:BHC
Bausch Health Companies — Shareholder Meeting (May 2017)
22 slides from Bausch Health Companies's shareholder meeting presentation, May 2, 2017
Slide 1: 2017 Annual Meeting Of Shareholders
2017 Annual Meeting Of Shareholders MAY 2, 2017 Laval, Quebec, CANADA
Slide 2: Introductions
Introductions BOARD OF DIRECTORS Joseph C. Richard U. Dr. Frederic N. D. Robert Dr. Argeris (Jerry) Papa DeSchutter Eshelman Hale Karabelas Chairman Sarah B. Robert N. Russel C. Thomas W. Amy B. Kavanagh Power Robertson Ross, Sr. Wechsler, M.D. 1
Slide 3: Remarks from Chairman & CEO Joseph C. Papa
Remarks from Chairman & CEO Joseph C. Papa 2017 Annual Meeting of Shareholders May 2, 2017 2
Slide 4: Forward-Looking Statements
Forward-Looking Statements Certain statements made in this presentation may constitute forward-looking statements, including, but not limited to, statements regarding expected future performance of Valeant Pharmaceuticals International, Inc. (“Valeant” or the “Company”), including guidance with resp
Slide 5: Non-GAAP Information
Non-GAAP Information Recent Assessment of Financial Performance Measures Recently, the Company’s new management team undertook an evaluation of how it would measure the financial performance of the Company going forward. In evaluating its financial performance measures, the Company considered its re
Slide 6: Our Impact on Health Care Today
Our Impact on Health Care Today Every day up to 150 million people around the world use a Valeant product 5
Slide 7: Our Mission and Vision
Our Mission and Vision OUR VISION TO BE YOUR TRUSTED HEALTH CARE PARTNER Quality Customer Health care Innovation Efficiency People Focused Outcomes MISSION To Improve People’s Lives With Our Health Care Products 6
Slide 8: Valeant's Three-Part Strategy
Valeant’s Three-Part Strategy OUR MISSION To Improve People’s Lives With Our Health Care Products STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ 7
Slide 9: 2016 Valeant Stabilization Plan
2016 Valeant Stabilization Plan 1. Drive Engagement • Re-recruit Valeant employees and add outside talent • Invest in relationships with patients, prescribers, payers and investors 2. Reallocate Strategic Resources on Core Businesses • Focus on Dermatology, Gastroenterology and Eye Care • Target R&D
Slide 10: Delivering on Commitments: New Leadership Team
Delivering on Commitments: New Leadership Team NEW LEADERSHIP HIRES Paul Herendeen Christina Ackermann Bill Humphries Executive Vice President, Finance Executive Vice President Executive Vice President, Chief Financial Officer General Counsel Dermatology Scott Hirsch Louis Yu Sam Eldessouky Senior V
Slide 11: Delivering on Commitments: Re-recruited Our Passionate Employees
Delivering on Commitments: Re-recruited Our Passionate Employees 10
Slide 12: Delivering on Commitments: Focus on Products and Patients
Delivering on Commitments: Focus on Products and Patients The Prescribing Information for Migranal includes a boxed warning about serious and/or life-threatening peripheral ischemia. 11
Slide 13: Delivering on Commitments: Rebuilding Partnerships
Delivering on Commitments: Rebuilding Partnerships SUPPLIER OF CANADA’S MOST THE YEAR TRUSTED BRANDS for U.S. Manufacturing in for Contact Consumables and Health Lens Solution & Wellness Solta’s Clear + Biotrue® Ocuvite Waterford, Brilliant pélo™ ONEday Ireland plant topped a Polish Aesthetic Most P
Slide 14: Delivering on Commitments: Execution in 2016
Delivering on Commitments: Execution in 2016 Launched New Prior Authorization Program for Dermatology/Dermatology Rx Recovery Continued Consistent Growth in Consumer Business Initiated Xifaxan® (rifaximin) New Formulation Activities/PCP Strategy Stabilized Salesforce Launched Relistor® Oral (methyln
Slide 15: Delivering on Commitments: Simplifying the Business
Delivering on Commitments: Simplifying the Business • We have simplified our operating model by divesting or agreeing to divest: – Skincare - CeraVe®, AcneFree® & AMBI® – Dendreon (expected to close mid-year) – Synergetics OEM – Ruconest® – Brodalumab EU Rights – Delta (Brazil) – Euvipharm (Vietnam)
Slide 16: Delivering on Commitments: Reducing Debt
Delivering on Commitments: Reducing Debt • We reiterate our August 2016 expectation to pay down $5B of debt from divestiture proceeds and free cash flow within an 18 month timeframe of that initial statement. • Stable current and forecasted liquidity position • $1.84B in permanent debt repayment in
Slide 17: The Future of Valeant
The Future of Valeant OUR MISSION To Improve People’s Lives With Our Health Care Products STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ Hired new management team Lead in our categories Strengthen balance sheet Fixing derm Focus on specialty markets Launch new Growing Salix Focus on markets wit
Slide 18: Investing in the New Valeant Business
Investing in the New Valeant Business Salix Primary Care Dermatology Bausch + Lomb Salesforce • Increasing field force by 40% • Increasing market access team to support • Investing in contact lens manufacturing Walgreens and Independent Pharmacies capabilities to yield improved capacity model and co
Slide 19: Anticipated R&D Catalysts in 2017
Anticipated R&D Catalysts in 2017 • SAN-300 (Rheumatoid Arthritis) Phase II data read out H1 • enVista® Trifocal (Intraocular Lens) Initiate IDE study in H1 • New Material (Ophthalmic Viscosurgical Device); Initiate IDE in H1 • Loteprednol Gel 0.38% (Ocular Inflammation) Complete Phase III enrollmen
Slide 20: R&D Spotlight
R&D Spotlight SILIQ™ (brodalumab) Approved • Total U.S. Psoriasis Market : Estimated ~$7B in 2018 • Approved on Feb 15, 2017 for the treatment of moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost resp
Slide 21: We Have Stabilized – Beginning Turnaround
We Have Stabilized – Beginning Turnaround OUR MISSION To Improve People’s Lives With Our Health Care Products STABILIZE TURNAROUND TRANSFORM 2016 2017-2018 2018+ Hired new management team Lead in our categories Strengthen balance sheet Fixing derm Focus on specialty markets Launch new Growing Salix
Slide 22: Question & Answer Period
Question & Answer Period 2017 Annual Meeting of Shareholders 21
Bausch Health Companies — Shareholder Meeting (May 2017) on 6ix